Novel High-Throughput Microwell Spectrophotometric Assay for One-Step Determination of Lorlatinib, a Novel Potent Drug for the Treatment of Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer

Background and Objectives: Lorlatinib (LOR) belongs to the third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors. People who are diagnosed with ALK-positive metastatic and advanced non-small cell lung cancer (NSCLC) are eligible to get it as a first-line treatment option after...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Hossaini, Abdullah M., Darwish, Ibrahim A., Darwish, Hany W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10143429/
https://www.ncbi.nlm.nih.gov/pubmed/37109714
http://dx.doi.org/10.3390/medicina59040756

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10143429/
https://www.ncbi.nlm.nih.gov/pubmed/37109714
http://dx.doi.org/10.3390/medicina59040756

Ejemplares similares